Abstracts tagged "psoriasis"

Abstract Number: 2502 • 2019 ACR/ARP Annual Meeting
Normalization of Inflammatory Gene Expression and Cellular Markers by Abatacept in the Skin Lesions of Psoriatic Arthritis Patients: A Biopsy Substudy of a Phase III Study
Jennifer Belasco¹, Sandra Garcet ¹, Mustimbo roberts ², Judilyn Fuentes-Duculan ¹, Norma Kunjravia ¹, Inna Cueto ¹, Israel Coats ¹, Xuan Li ¹, Philip Mease ³, Alice Gottlieb ⁴, Oliver FitzGerald ⁵ and James Krueger ¹, ¹The Rockefeller University, New York, NY, ²Bristol-Myers Squibb, Princeton, NJ, ³Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, ⁵University College Dublin, Dublin, Ireland
Background/Purpose: Abatacept (ABA), a selective T-cell co-stimulation modulator, has been shown to improve disease activity in patients with psoriatic arthritis (PsA), but its effect on…
Abstract Number: 1526 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in a Phase 3 Study
Wendy Cantrell ¹, Patricia Lee ², Emil Tanghetti ³, Alan Mendelsohn⁴, Jeff Parno ⁴, Stephen Rozzo ⁴ and Wilson Liao ⁵, ¹Department of Dermatology, University of Alabama Birmingham, Birmingham, AL, USA; Dermatology at the Whitaker Clinic, Birmingham, AL, USA, Birmingham, AL, ²Center for Clinical Studies, Webster, TX, USA, Webster, TX, ³Center for Dermatology and Laser Surgery, Sacramento, CA, USA, Sacramento, CA, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁵Department of Dermatology, University of California San Francisco, San Francisco, CA, USA, San Francisco, CA
Background/Purpose: We assessed residual plaque psoriasis in patients successfully treated with anti–interleukin-23p19 monoclonal antibody tildrakizumab (TIL) who interrupted treatment, relapsed, and were retreated vs continuously…
Abstract Number: 2504 • 2019 ACR/ARP Annual Meeting
Differential Expression of Human Endogenous Retroviruses in Psoriatic Disease
Remy Pollock¹, Rohan Machhar ¹, Laila Zaman ¹, Dafna Gladman ² and Vinod Chandran ³, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Human endogenous retroviruses (HERV) are the stably inherited remnants of ancient retroviruses that infected the ancestral germline. A growing body of research has associated…
Abstract Number: 1527 • 2019 ACR/ARP Annual Meeting
Limited Changes in Hematological Parameters During Tildrakizumab Treatment: Post Hoc Analysis of Data from the Tildrakizumab Psoriasis Clinical Program
Holly Glover ¹, Kristine Kucera ², Alan Mendelsohn³, Jeff Parno ³, Stephen Rozzo ³, Frank Ferritto ⁴ and Renata Block ⁵, ¹Dermatology and Skin Cancer Surgery Center, McKinney, TX, USA, McKinney, TX, ²North Texas Dermatology, Richardson, TX, USA, Richardson, TX, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁴Polley Dermatology, Wilson, NC, USA, Wilson, NC, ⁵Pinski Dermatology & Cosmetic Surgery, Chicago, IL, USA, Chicago, IL
Background/Purpose: Tildrakizumab (TIL) is a high-affinity, anti–interleukin‐23p19 monoclonal antibody with demonstrated efficacy for the treatment of chronic plaque psoriasis in a phase 2b (P05495 [NCT01225731])…
Abstract Number: 2505 • 2019 ACR/ARP Annual Meeting
Can Biologics “Prevent” the Development of Psoriatic Arthritis in Psoriasis Patients? Data from a Large University Hospital Cohort in Argentina
Luciano Fernando Lo Giudice¹, Maria Laura Acosta Felquer ¹, Luis Daniel Mazzuoccolo ², Maria Laura Galimberti ² and Enrique Soriano ³, ¹Hospital Italiano de Buenos Aires, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: As psoriasis (Pso) commonly precedes psoriatic arthritis (PsA), an important unanswered question is whether treatment of Pso might influence the development of PsA in…
Abstract Number: 1538 • 2019 ACR/ARP Annual Meeting
The Effects of Apremilast Therapy on Deployability in Active Duty U.S. Army Soldiers with Plaque Psoriasis and Psoriatic Arthritis
Andrew Price¹, Vanya Wagler ², Chase Donaldson ¹ and Patrick Mastin ¹, ¹William Beaumont Army Medical Center, El Paso, TX, ²United Regional Physician Group, Wichita Falls, TX
Background/Purpose: Apremilast is a novel oral phosphodiesterase 4 inhibitor that is used for plaque psoriasis (PsO) and psoriatic arthritis (PsA). This medicine is unique in…
Abstract Number: 2743 • 2019 ACR/ARP Annual Meeting
Characterizing the Epigenomic Landscape of Psoriasis Patients Destined to Develop Psoriatic Arthritis
Remy Pollock¹, Rohan Machhar ¹, Vinod Chandran ² and Dafna Gladman ³, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²University Health Network, University of Toronto, Toronto, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Approximately 30% of psoriasis patients develop psoriatic arthritis (PsA), an inflammatory musculoskeletal disease, usually after psoriasis onset. A large proportion of individuals with PsA…
Abstract Number: 1556 • 2019 ACR/ARP Annual Meeting
Exposure–Response Modeling of an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, BMS-986165, for Pain Visual Analog Scale Score, in Patients with Psoriasis and Musculoskeletal Symptoms
Jun Shen¹, Anjaneya Chimalakonda ¹, Miroslawa Nowak ¹, John Throup ¹, Subhashis Banerjee ¹ and Ihab Girgis ¹, ¹Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: BMS-986165 is an oral, selective inhibitor of TYK2, an enzyme that activates signal transducer and activator of transcription (STAT)-dependent cytokine signaling pathways, including the…
Abstract Number: 1912 • 2019 ACR/ARP Annual Meeting
High Dimensional Flowcytometric Profiling Distinguishes Psoriasis and Psoriatic Arthritis
Michelle Mulder¹, Juul van den Reek ², Elke de Jong ², Bram van Cranenbroek ², Ruben Smeets ², Irma Joosten ², Xuehui He ³, Frank van den Hoogen ¹, Hans Koenen ³ and Mark Wenink ¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Radboudumc, Nijmegen, Netherlands, ³Radboudumc, Njimegen, Netherlands
Background/Purpose: Psoriasis (Pso) is a common chronic inflammatory skin disease. About 30% of Pso patients develop psoriatic arthritis (PsA), a chronic inflammation of joints and…
Abstract Number: 2092 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of the Adjuvanted Recombinant Zoster Vaccine in Adults with Pre-existing Potential Immune Mediated Diseases: A Pooled Post-hoc Analysis on Two Parallel Randomized Trials
Alemnew Dagnew¹, Debora Rausch ², Caroline Hervé ³, Toufik Zahaf ⁴ and Anne Schuind ¹, ¹GSK, Rockville, MD, ²GSK, Philadelphia, PA, ³GSK, Wavre, Belgium, ⁴GSK, Rixensart, Belgium
Background/Purpose: The increased risk of herpes zoster (HZ) in older adults is attributable to age-related decline in immunity. In 2 pivotal studies, ZOE-50 (NCT01165177) and…
Abstract Number: 2120 • 2019 ACR/ARP Annual Meeting
No Evidence of an Increased Risk of Serious Infections Among 3 Classes of Biologics for Psoriasis or Psoriatic Arthritis: A Retrospective Real-World Cohort Study
Xintong Li ¹, Kathleen M Andersen², Hsien-Yen Chang ³, G. Caleb Alexander ⁴ and Jeffrey Curtis ⁵, ¹Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,, Baltimore, MD, ³Johns Hopkins Bloomberg School of Public Health, Baltimore, ⁴Johns Hopkins Bloomberg School of Public Health. Center for Drug Safety and Effectiveness, Baltimore, MD, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The real-world risk of serious infections associated with interleukin (IL) and tumor necrosis factor-alpha (TNF-α) inhibitors for patients with psoriasis (PsO) and psoriatic arthritis…
Abstract Number: 104 • 2019 ACR/ARP Annual Meeting
Novel, Selective, Orally Active PAD4 Inhibitors for the Treatment of Autoimmune Disorders
Santosh Vishwakarma¹, Gurulingappa Hallur ¹, Himanshu Agrawal ¹, Sharad Singh ¹, Annasaheb Kalange ¹, Seema Chikkur Gangadhar ¹, Shuvranshu PraharaJ ¹, Nafees Ahmad Quresh ¹, Srikanth Kanagal Gopinath ¹, Krishnakumar V ¹, Sameer Mahmood ¹, Rudresh G ¹, Mohd Zainuddin ¹, Rajendra Kristam ¹, Ishtiyaque Ahmad ¹, Ramachandraiah Gosu ¹, Purra Buchi Reddy ¹, N V S K Rao ¹, Saloni Mehra ², Jeyaraj D A ¹, Takeshi Yura ¹, Saravanakumar dhakshinamoorthy ¹, Sriram Rajagopal ¹, Dhanalakshmi Sivanandhan ³ and Sridharan Rajagopal ³, ¹Jubilant Biosys, Bangalore, India, ²Jubilant Chemsys, Noida, India, ³Jubilant Therapeutics, Bangalore, India
Background/Purpose: Citrullination of proteins is catalyzed by a family of enzymes called the peptidylarginine deiminases (PADs). While the citrullinated proteins may have physiological roles in differentiation,…
Abstract Number: 2145 • 2019 ACR/ARP Annual Meeting
Long-term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Incidence of Severe Infections Through 3 Years (148 Weeks) from 2 Phase 3 Trials
Diamant Thaçi ¹, Kristian Reich ², Jo Lydie Lambert ³, Lars Iversen ⁴, Andrea Peserico ⁵, Ignasi Pau-Charles ⁶, Andrew Blauvelt⁷ and Christopher Griffiths ⁸, ¹Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, Lübeck, Germany, ²University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Skinflammation®, Hamburg, Germany; Dermatologikum Berlin, Berlin, Germany, Hamburg, Germany, ³Department of Dermatology, Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ⁴Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ⁵Clinica Dermatologica, Department of Medicine-DIMED University of Padua, Padua, Italy, Padua, Italy, ⁶Almirall R&D, Barcelona, Spain, Barcelona, Spain, ⁷Oregon Medical Research Center, Portland, OR, USA, Portland, OR, ⁸Centre for Dermatology Research, The University of Manchester, Manchester, UK, Manchester, United Kingdom
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. The objective of this study was to evaluate…
Abstract Number: 291 • 2019 ACR/ARP Annual Meeting
Factors Explaining Patient Perspective in Psoriasis and Psoriatic Arthritis: The Role of Inflammation and Structural Damage Detected by Ultrasound
Tania Gudu¹, Ilaria Padovano ¹, Hélène Gouze ², François Vidal ¹, Emmanuel Mahé ³, Leire Lara Gonzalez ⁴, Alexis Guyot ⁴, Philippe Saiag ⁴, Isabelle Bourgault Villada ⁴, Sophie Ruel-Gagné ¹, Gilles Hayem ¹, Félicie Costantino ⁵, Maxime Breban ⁶ and Maria-Antonietta D’Agostino ⁷, ¹Rheumatology Department, APHP, Ambroise Paré Hospital, Boulogne Billancourt, France, ²Rheumatology Department, APHP, Ambroise Paré Hospital, Bolougne Billancourt, France, ³Dermatology Department, Victor Dupouy Hospital, Argenteuil, France, ⁴Dermatology Department, Ambroise Paré Hospital, Boulogne Billancourt, France, ⁵UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, France, ⁶UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, ⁷Department of Rheumatology, APHP, Hôpital Ambroise Paré, Paris, France
Background/Purpose: Patient reported outcomes (PROs) reflect patients’ opinion on disease activity, impact of disease, quality of life (QoL), disability and are essential in the assessment…
Abstract Number: 2447 • 2019 ACR/ARP Annual Meeting
Characteristics of Psoriasis Patients with Subclinical Signs of Musculoskeletal Involvement Detected by Fluorescence Optical Imaging and Confirmed by MRI-assessment
Michaela Koehm¹, Sarah Ohrndorf ², Tanja Rossmanith ³, Hans-Eckhard Langer ⁴, Marina Backhaus ⁵, Gerd Burmester ⁶, Siegfried Wassenberg ⁷, Benjamin Köhler ⁸, Harald Burkhardt ¹ and Frank Behrens ¹, ¹Rheumatology Goethe-University Frankfurt & Fraunhofer IME-TMP, Frankfurt, Germany, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Fraunhofer IME-TMP, Frankfurt, Germany, ⁴RHIO, Düsseldorf, Germany, ⁵Park-Klinik Weissensee, Berlin, Germany, ⁶Charité—University Medicine Berlin, Berlin, Germany, ⁷Centre of Rheumatology, Ratingen, Germany, ⁸Rheumazentrum Ratingen, Ratingen, Germany
Background/Purpose: Psoriasis (Pso) is one of the most common chronic inflammatory skin diseases in Europe. Psoriatic arthritis (PsA) is closely associated to Pso whereas the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.